LAMA
Umeclidinium
Brand names: Incruse Ellipta
Adult dose
Dose: 1 inhalation (62.5 micrograms) OD
Route: Inhaled
Frequency: OD
Clinical pearls
- COPD maintenance bronchodilation
- Once-daily Ellipta dry powder
Contraindications
- Hypersensitivity
Side effects
- Dry mouth
- Headache
- Cough
- Acute glaucoma
- Urinary retention
- AF
Interactions
- Other antimuscarinics
Monitoring
- Symptoms
- Inhaler technique
Reference: BNF; NICE NG115; GOLD; https://bnf.nice.org.uk/drugs/umeclidinium/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Pathways
- Acute Asthma in Adults · BTS/SIGN British Guideline on Asthma 2019; NICE NG80
- Pulmonary Embolism Assessment · NICE NG158; ESC 2019 PE Guidelines
- Acute Exacerbation of COPD (AECOPD) · NICE NG115; GOLD 2024
- Spontaneous Pneumothorax (Adult) · BTS Pleural Disease 2023
- Atypical Pneumonia (Legionella / Mycoplasma / Chlamydophila) · BTS 2023; IDSA
- COPD Exacerbation Management · NICE NG115 / GOLD 2024